… that the BRAF V600E mutation is … BRAF V600E mutation should be considered as a poor
prognostic marker in PTC and may lead to better management for individual patients. Cancer …

… : The BRAF V600E mutation is closely related to serum Tg elevation after treatment with
iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a …

… and 9,951 (39.4%) were tested negative for BRAF mutation. Negative status of BRAFV600E
mutation … By contrast, positive status of BRAFV600E mutation was a significant predictor of …

… to investigate the frequency of the BRAFV600E mutation in PTC with and … It was then analyzed
for the BRAFV600E mutation by … The BRAFV600E mutation was present in 27 (72.9%) of …

… mutation is not a determinant of the metastatic potential of PTC. Papillary thyroid cancers are
… determine the most appropriate use of the BRAF mutation as a clinical marker, whereas we …

… To investigate the mutant status of BRAF gene and analyze its relationship to epidemiological
risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the …

… targeted at the BRAF V600E mutation, BRAF V600E mutation testing by immunohistochemistry
should be considered in the routine histological evaluation of papillary thyroid carcinoma. …

… BRAF V600E mutation has been adopted as a prognostic factor in papillary thyroid
carcinoma … However, it remains unclear whether routine BRAF mutation analysis is useful in …

… This study tests the prevalence of BRAF V600E mutation in thyroid cancer patients in Indian
… analyzed 140 thyroid tumor specimens for BRAF gene mutation at codon 600 using mutant-…

… nodules, with a prevalence of 62% mutated BRAF PTCs and variable … BRAF V600E
mutation analysis could increase the diagnostic accuracy of FNAB for PTC in suspicious thyroid …